1
|
Hu N, Tanaka H, Kakino R, Yoshikawa S, Miyao M, Akita K, Isohashi K, Aihara T, Nihei K, Ono K. Evaluation of a treatment planning system developed for clinical boron neutron capture therapy and validation against an independent Monte Carlo dose calculation system. Radiat Oncol 2021; 16:243. [PMID: 34952608 PMCID: PMC8709965 DOI: 10.1186/s13014-021-01968-2] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2021] [Accepted: 12/15/2021] [Indexed: 11/16/2022] Open
Abstract
Boron neutron capture therapy (BNCT) for the treatment of unresectable, locally advanced, and recurrent carcinoma of the head and neck cancer has been approved by the Japanese government for reimbursement under the national health insurance as of June 2020. A new treatment planning system for clinical BNCT has been developed by Sumitomo Heavy Industries, Ltd. (Sumitomo), NeuCure® Dose Engine. To safely implement this system for clinical use, the simulated neutron flux and gamma ray dose rate inside a water phantom was compared against experimental measurements. Furthermore, to validate and verify the new planning system, the dose distribution inside an anthropomorphic head phantom was compared against a BNCT treatment planning system SERA and an in-house developed Monte Carlo dose calculation program. The simulated results closely matched the experimental results, within 5% for the thermal neutron flux and 10% for the gamma ray dose rate. The dose distribution inside the head phantom closely matched with SERA and the in-house developed dose calculation program, within 3% for the tumour and a difference of 0.3 Gyw for the brain.
Collapse
Affiliation(s)
- Naonori Hu
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka-fu Takatsuki-shi Daigakumachi 2-7, Takatsuki, Japan. .,Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kyoto, Japan.
| | - Hiroki Tanaka
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kyoto, Japan
| | - Ryo Kakino
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka-fu Takatsuki-shi Daigakumachi 2-7, Takatsuki, Japan
| | - Syuushi Yoshikawa
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka-fu Takatsuki-shi Daigakumachi 2-7, Takatsuki, Japan
| | - Mamoru Miyao
- Central Department of Radiology, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Japan
| | - Kazuhiko Akita
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka-fu Takatsuki-shi Daigakumachi 2-7, Takatsuki, Japan
| | - Kayako Isohashi
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka-fu Takatsuki-shi Daigakumachi 2-7, Takatsuki, Japan
| | - Teruhito Aihara
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka-fu Takatsuki-shi Daigakumachi 2-7, Takatsuki, Japan
| | - Keiji Nihei
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka-fu Takatsuki-shi Daigakumachi 2-7, Takatsuki, Japan.,Department of Radiation Oncology, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Japan
| | - Koji Ono
- Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka-fu Takatsuki-shi Daigakumachi 2-7, Takatsuki, Japan
| |
Collapse
|